Beximco Pharmaceuticals Limited (AIM: BXP)

Market Cap	214.68M
Revenue (ttm)	309.81M
Net Income (ttm)	38.33M
Shares Out	n/a
EPS (ttm)	0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	70,218
Open	21.35
Previous Close	21.50
Day's Range	21.20 - 22.00
52-Week Range	19.33 - 45.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 4, 2024

About Beximco Pharmaceuticals

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1976
• Employees: 5,700
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: BXP

Financial Performance

In 2023, Beximco Pharmaceuticals's revenue was 39.27 billion, an increase of 13.26% compared to the previous year's 34.67 billion. Earnings were 4.61 billion, a decrease of -9.94%.

Financial numbers in BDT